Date: 2015-07-27
Type of information: Nomination
Compound:
Company: CTI BioPharma - previously known as Cell Therapeutics (USA - WA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 27, 2015, CTI BioPharma announced the appointment of Bruce J. Seeley as Executive Vice President and Chief Commercial Officer, reporting to James Bianco, M.D., CTI BioPharma\'s President and Chief Executive Officer. Bruce Seeley will serve on the executive leadership team, assuming responsibility for CTI BioPharma\'s commercial organization worldwide – including sales, marketing, commercial operations, medical affairs and supply chain. Bruce Seeley most recently served as Senior Vice President and General Manager of Diagnostics at NanoString Technologies, Inc. overseeing the launch of the diagnostic product Prosigna® for early stage breast cancer. Before joining NanoString, Seeley was Executive Vice President of Commercial at Seattle Genetics where he built and led the commercial organization, including marketing, sales and managed markets. While at Seattle Genetics, Seeley successfully launched the company\'s first product, Adcetris®, a targeted therapy for lymphoma. Seeley also previously held key leadership positions in marketing at Genentech, including as Senior Director, Oncology Marketing, HER2 Brands, where he led the launch of Herceptin® in adjuvant breast cancer. Seeley also held various roles at Aventis Pharmaceuticals Inc. (a part of Sanofi) in global and U.S. marketing, sales and new product commercialization and licensing, and in sales at BMS. In connection with the transition of medical affairs to the new Chief Commercial Officer, Dr. Jack Singer assumes the position of Chief Scientific Officer and will continue to serve as Executive Vice President, Interim Chief Medical Officer and Global Head of Translational Medicine.
Financial terms:
Latest news:
